Ridinilazole + Vancomycin
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Infection
Conditions
Clostridioides Difficile Infection
Trial Timeline
May 19, 2021 → Sep 28, 2022
NCT ID
NCT04802837About Ridinilazole + Vancomycin
Ridinilazole + Vancomycin is a phase 3 stage product being developed by Summit Therapeutics for Clostridioides Difficile Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT04802837. Target conditions include Clostridioides Difficile Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04802837 | Phase 3 | Terminated |
| NCT03595553 | Phase 3 | Completed |
Competing Products
7 competing products in Clostridioides Difficile Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 | AstraZeneca | Phase 2 | 52 |
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 33 |
| C.difficile vaccine | Pfizer | Phase 3 | 76 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 47 |
| SER-109 | Seres Therapeutics | Pre-clinical | 15 |
| SER-109 | Seres Therapeutics | Phase 3 | 69 |